• Home
  • For Owners
    • Navigating The Diagnosis
    • FAQs
    • Treatments
    • Caregiver Burden
    • Resources
    • Financial Aid
    • Find a Specialist
    • At Home Care
    • Community
  • For Veterinarians
    • Hemangio Journal
    • Clinical Trials
  • About Us
  • Donate
  • Contact Us
Boron Neutron Capture Therapy Targets HSA Cells

Boron Neutron Capture Therapy Targets HSA Cells

by Effie Machiavello | May 17, 2026 | Hemangio Journal

A recent study has tested a novel radiation therapy called boron neutron capture therapy (BNCT) on canine HSA cells for the first time. BNCT is a two-step process. First, a boron compound called BPA is injected. Cancer cells take up this compound through a protein on...
What Ozonated Glycerin Can Do for Hemangiosarcoma

What Ozonated Glycerin Can Do for Hemangiosarcoma

by Effie Machiavello | May 10, 2026 | Treatments

Standard treatments for hemangiosarcoma do important work. But there’s also quiet progress happening beyond them. Doctors and scientists exploring new paths, revisiting old ones, and finding things that actually help our dogs feel better. Ozone therapy seems to...
New Lab Models Mimic HSA Progression from Primary Tumor to Metastasis

New Lab Models Mimic HSA Progression from Primary Tumor to Metastasis

by Effie Machiavello | Apr 4, 2026 | Hemangio Journal

A recent study from Tokyo University of Agriculture and Technology has developed a new way to study Hemangiosarcoma in the lab. The researchers successfully grew 2.5D organoids using tissue from dogs with HSA and compared them to organoids from benign nodular...
A Guide to Safely Using Supplements for Canine Hemangiosarcoma

A Guide to Safely Using Supplements for Canine Hemangiosarcoma

by Effie Machiavello | Mar 7, 2026 | At Home Care, Treatments

The moment you’re facing hemangiosarcoma, whether it’s suspected, diagnosed, or you’re in that awful waiting period for results, you’ll feel like no effort is too much. You look at your pup’s face, and a question inevitably arrives: What...
Metastatic Site as Prognostic Variable in Splenic HSA

Metastatic Site as Prognostic Variable in Splenic HSA

by Effie Machiavello | Feb 25, 2026 | Hemangio Journal

While splenectomy combined with adjuvant chemotherapy remains the standard of care for hemangiosarcoma, survival times are notoriously short, particularly for dogs with stage III disease, where median survival times often range from just 68 to 136 days. For decades,...
« Older Entries

Recent Posts

  • Boron Neutron Capture Therapy Targets HSA Cells
  • What Ozonated Glycerin Can Do for Hemangiosarcoma
  • New Lab Models Mimic HSA Progression from Primary Tumor to Metastasis
  • A Guide to Safely Using Supplements for Canine Hemangiosarcoma
  • Metastatic Site as Prognostic Variable in Splenic HSA

Recent Comments

No comments to show.
14 High Point Road
East Hampton, NY 11937
Phone: 1-631-204-3355

info@hemangio.com

FOR PET OWNERS

Navigating Diagnosis
FAQs
Treatments
Caregiver Burden
Resources
Financial Aid
Find a Specialist
At Home Care

FOR VETERINARIANS

Hemangio Journal
Clinical Trials

OTHER LINKS

About Us
Donate
Contact Us

Copyright Hermangio 2026. All Rights  Reserved.

Privacy Policy | Terms of Use